8-K

QuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of earliest event reported: January 17, 2002

PHARMACOPEIA, INC.
(Exact name of registrant as specified in charter)

Delaware	0-27188	33-0557266
(State of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

	CN 5350, Princeton, New Jersey (Address of Principal Executive Offices)	08543-5350 (Zip Code)
(609) 452-3600 (Registrant's telephone number, including area code)

Item 5. Other Events and Regulation FD Disclosure.

        On January 17, 2002, Pharmacopeia, Inc. issued a press release announcing that Pharmacopeia and Eos Biotechnology, Inc. have mutually terminated the Agreement and Plan of Merger and Reorganization, dated as of August 21, 2001, by and among Pharmacopeia, Eagle Acquisition Corporation, a wholly-owned subsidiary of Pharmacopeia, and Eos.

        The press release has been filed as an exhibit to this report and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c)

Exhibits:

Exhibit #	Description
99.1	Press release dated January 17, 2002
99.2	Termination Agreement, dated January 17, 2002, by and between Pharmacopeia, Inc. and Eos Biotechnology, Inc.

2

SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARMACOPEIA, INC.
Date: January 23, 2002	By:    /s/  JOSEPH A. MOLLICA        Joseph A. Mollica, Ph.D.         Chief Executive Officer

3

EXHIBIT INDEX

99.1	Press release dated January 17, 2002
99.2	Termination Agreement, dated January 17, 2002, by and between Pharmacopeia, Inc. and Eos Biotechnology, Inc.

QuickLinks

SIGNATURE
EXHIBIT INDEX

EX-99.1

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 99.1

FOR IMMEDIATE RELEASE

PHARMACOPEIA AND EOS TERMINATE MERGER AGREEMENT
Pharmacopeia Special Meeting of Stockholders Cancelled

        PRINCETON, NJ, January 17, 2002—Pharmacopeia, Inc. (Nasdaq: PCOP) and Eos Biotechnology today announced that their Boards of Directors have mutually agreed to terminate the merger agreement signed in August 2001. Pharmacopeia's special meeting of stockholders scheduled for 9:00 a.m. on Friday, January 18, 2002 has been cancelled.

        "We remain optimistic about the future prospects of the science, technology and people at Pharmacopeia," said Joseph A. Mollica, PhD, Chairman, President and CEO. "We believe there are many ways in which we can prosper by adding to and leveraging our existing biology and chemistry capabilities. We will continue to pursue the many alternatives available to us."

        Pharmacopeia (www.pharmacopeia.com) provides enabling science and technology that accelerates and improves the drug discovery and chemical development processes. Pharmacopeia's Drug Discovery segment integrates proprietary small molecule combinatorial and medicinal chemistry, high-throughput screening, in-vitro pharmacology, computational methods and informatics to discover and optimize lead compounds. Pharmacopeia's software subsidiary, Accelrys, develops and commercializes molecular modeling and simulation software for the life sciences and materials research, cheminformatics and decision support systems, and bioinformatics tools including gene sequence analysis. The business also provides consulting services to its customers in drug discovery and chemical development. Pharmacopeia employs approximately 800 people, generated 2000 revenues of approximately $119 million, and is headquartered in Princeton, NJ.

        When used anywhere in this document, the words "expects", "believes", "anticipates", "estimates" and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Pharmacopeia and the timing, benefits and other aspects of the proposed merger. Pharmacopeia has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Pharmacopeia's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the SEC, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Contacts:
Bruce Myers	Sue Rodney
Chief Financial Officer	Manager, Investor Relations
858/799-5575	(609) 452-3643
bmyers@accelrys.com	srodney@pharmacop.com

QuickLinks

PHARMACOPEIA AND EOS TERMINATE MERGER AGREEMENT

EX-99.2

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 99.2

TERMINATION AGREEMENT

        Pursuant to Section 8.1(a) of the Agreement and Plan of Merger and Reorganization dated as of August 21, 2001 among Pharmacopeia, Inc. ("Pharmacopeia"), Eos Biotechnology, Inc. ("Eos") and Eagle Acquisition Corporation (the "Agreement"), Pharmacopeia and Eos hereby agree to terminate the Agreement and the transactions contemplated thereby.

        Eos and Pharmacopeia each agree (a) not to issue any press release or otherwise publicly disseminate any document or other written material, or make any other public statement, relating to the Agreement or the transactions contemplated thereby or the termination thereof without the prior approval of the other party, except to the extent required by law (and then only after consultation with the other party), and (b) not to make, directly or indirectly, disparaging or derogatory comments about the other party or parties (including such party's officers, directors, employees and shareholders).

        This Termination Agreement shall not affect the Confidentiality Agreement (as defined in the Agreement), which shall continue in full force and effect.

        This Termination Agreement may be signed in counterparts, each of which shall constitute an original and all of which taken together shall constitute one and the same instrument.

        IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on this 17th day of January, 2002.

PHARMACOPEIA, INC.
By:	/s/ Joseph A. Mollica, Ph.D.
	Name:	Joseph A. Mollica, Ph.D.
	Title:	Chairman of the Board of Directors, Chief Executive Officer and President
EOS BIOTECHNOLOGY, INC.
By:	/s/ David W. Martin, Jr.
	Name:	David W. Martin, Jr.
	Title:	President and Chief Executive Officer

QuickLinks

TERMINATION AGREEMENT